Agilon Health price target raised to $4 from $3 at Benchmark

Benchmark analyst Bill Sutherland raised the firm’s price target on Agilon Health (AGL) to $4 from $3 and keeps a Buy rating on the shares following what the firm describes as a “largely in-line 4Q print and an appropriately cautious outlook for FY25.” FY25 is “a transition year” with reduced AEBITDA loss guidance on a targeted roughly 4% decline in Medicare Advantage membership as the company exits two unprofitable physician partnerships, the analyst noted.